Fate Therapeutics - FATE Operating profit EBITDA
Fate Therapeutics, Inc. (FATE) consolidated EBITDA demonstrates a dependence on medical test outcomes, while the 0.00 metric determines the parameter status. This trend relies on the high level of scientific expertise of the executives. Stability is ensured by the non-cyclical nature of the fight against cancer, which remains independent of economic conditions. The current trend confirms that development is based on capital-intensive R&D research and support from major funds.
Fate Therapeutics (FATE) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Aggregate Debt to Equity Fate Therapeutics, Inc.|FATE - Long-Term Debt to Capital|Short-Term Debt to Capital Fate Therapeutics Inc|FATE - Company Total Debt|Debt to Book Capital Fate Therapeutics|FATE - Company Long-Term Debts|Short-Term Debt Fate Therapeutics|Intermediate Coverage Ratio fatetherapeutics.com
- earnings and market ratios statistics:
FATE - Net Income|Future Net Profit Fate Therapeutics, Inc.|FATE - P/E Multiple|Future Price to Earnings Multiple fatetherapeutics.com|FATE - PEG Multiple|Company Value to EBITDA Fate Therapeutics|FATE - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Fate Therapeutics|FATE - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth fatetherapeutics.com|FATE - Earnings per share growth in current year|Net earnings per share change forecast for next year Fate Therapeutics, Inc.
Fundamental company valuation:Fate Pharma FATE
The stability of Fate Therapeutics, Inc. (FATE) currently depends on the confirmation of its platform's safety, as the absence of commercial sales deprives the company of pricing power. By analyzing the history of operating profit in cash terms, an investor assesses the real cash flow from current operations; however, local peaks on this chart often signal an imminent cycle reversal and a potential decline in the asset's value.
Who Fate Therapeutics, Inc. competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit EBITDA PSNL|ERAS: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA DCTH (Delcath Systems)|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|AURA: Operating profit before deduction of amortization|Candel Therapeutics - Company profit before taxes, interest and amortization|ARAY: Operating profit EBITDA|Profit before interest, taxes and amortization SELLAS Life Sciences Group (SLS)|Operating profit before deduction of amortization ACTU|CTOR: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization HURA (TuHURA Biosciences, Inc.)|Company profit before taxes, interest and amortization TARA|Operating profit EBITDA WHWK (Aadi Bioscience)|Income before deduction of interest, taxes and amortization TCRX|Champions Oncology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization XBiotech Inc.|cel-sci.com (CVM) - Profit before payment of interest, taxes and amortization|OS Therapies, Inc. - Income before deduction of interest, taxes and amortization|RADX (Radiopharm Theranostics) - Operating profit EBITDA|Operating profit EBITDA Artiva|Profit before payment of interest, taxes and amortization Adlai Nortye Ltd. (ANL)|VERU: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA TPST (Tempest Tx)|Xilio Therapeutics Inc (XLO) - Profit before interest, taxes and amortization|RENB: Operating profit before deduction of amortization|MURA - Operating profit EBITDA|KAPA (kairospharma.com) - Operating profit before deduction of amortization|OKUR: Company profit before taxes, interest and amortization|GDTC (CytoMed Therapeutics Ltd) - Operating profit EBITDA|Curis Corp (CRIS) - Operating income before deduction of amortization|Operating profit EBITDA APLM|Operating profit before deduction of amortization tharimmune.com THAR|Profit before payment of interest, taxes and amortization Advanced Biomed ADVB|Operating income before deduction of amortization Genprex Inc. (GNPX)|CLDI: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization SBFM (sunshinebiopharma.com)|XBIO: Operating profit EBITDA|SLRX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Purple Biotech Ltd.|Operating profit before amortization AONC (AON)|Operating profit EBITDA BGNE|Operating profit before deduction of amortization Checkpoint Therapeutics Inc CKPT|Elevation Oncology - Operating profit before deduction of amortization|Operating income before deduction of amortization iCAD Inc. (ICAD)|Ikena - Operating profit EBITDA|Profit before deduction of interest, taxes, depreciation and amortization NTBL|VIRX: Operating profit EBITDA|MorphoSys Corporation (MOR) - Operating profit EBITDA|Operating profit before deduction of amortization NAYA|AAPGV (ascentage.com) - Company profit before taxes, interest and amortization
